Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2008 Oct-Nov;23(5):439–446. doi: 10.1177/1533317508320084

The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease

Sebastian Palmqvist 1, Oskar Hansson 2, Lennart Minthon 3, Elisabet Londos
PMCID: PMC10846192  PMID: 18955723

Abstract

Aims: Cube copying measures visuospatial ability, which is often impaired in Alzheimer's disease (AD). Cube copying was examined as an evaluation of cholinesterase inhibitor (ChEI) treatment in AD. Methods: Eighty-five ChEI-treated AD patients were included. Cube drawings made at prebaseline, baseline, 6 months, and 12 months were assessed. Cube drawings from 56 healthy individuals were also examined. Results : The healthy individuals remained stable in cube copying, whereas untreated AD patients deteriorated during a median period of 6 months. When treatment was given, the deterioration was interrupted. After 12 months, Mini-Mental State Examination (MMSE) had deteriorated compared with baseline whereas cube copying was unchanged.

Conclusions: The results indicate that cube copying can be used to evaluate ChEI treatment. It might also show a more long-lasting response to treatment than MMSE. Cube copying only measures a narrow cognitive function and can preferably be used with MMSE, which evaluates visuospatial ability poorly.

Keywords: Alzheimer's disease, cube copying, cholinesterase inhibitors, treatment outcome, box copying, Necker cube

Full Text

The Full Text of this article is available as a PDF (216.9 KB).

Contributor Information

Sebastian Palmqvist, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, University Hospital MAS, Malmö, Sweden, sebastian.palmqvist@skane.se .

Oskar Hansson, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, University Hospital MAS, Malmö, Sweden.

Lennart Minthon, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, University Hospital MAS, Malmö, Sweden.

References

  1. National Institutes of Health. Progress Report on Alzheimer's Disease. Washington, DC: US Department of Health and Human Services; 1999. [Google Scholar]
  2. Scalco MZ, van Reekum R. Prevention of Alzheimer disease. Encouraging evidence. Can Fam Physician. 2006;52:200-207. [PMC free article] [PubMed] [Google Scholar]
  3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593. doi:101002/14651858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Emre M., Aarsland D., Albanese A., et al: Rivastigmine for dementia associated with Parkinson's disease . N Engl J Med. 2004;351:2509-2518. [DOI] [PubMed] [Google Scholar]
  5. National Institute for Health and Clinical Excellence. Dementia: Supporting People With Dementia and Their Carers in Health and Social Care. London, UK: National Institute for Health and Clinical Excellence. [Google Scholar]
  6. Graham N., Emery T., Hodges JR Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004. ;75:61-71. [PMC free article] [PubMed] [Google Scholar]
  7. Filley C., Kelly J., Heaton R. Neuropsychologic features of early- and late-onset Alzheimer's disease . Arch Neurol. 1986;43:574-576. [DOI] [PubMed] [Google Scholar]
  8. Binetti G., Cappa S., Magni E., Padovani A., Bianchetti A., Trabucchi M. Visual and spatial perception in the early phase of Alzheimer's disease . Neuropsychology. 1998;12: 29-33. [DOI] [PubMed] [Google Scholar]
  9. Guerin F., Belleville S., Ska B. Characterization of visuoconstructional disabilities in patients with probable dementia of Alzheimer's type. J Clin Exp Neuropsychol . 2002;24:1-17. [DOI] [PubMed] [Google Scholar]
  10. Kirk A., Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol . 1991;48:73-77. [DOI] [PubMed] [Google Scholar]
  11. Kato M., Sano Y., Uno A. Constructive deficits in brain damaged patients: effects of the localized and /or diffuse cerebral lesions. Higher Brain Funct Res. 1988;8:305-319. [Google Scholar]
  12. Maeshima S. , Osawa A., Maeshima E., et al. Usefulness of a cube-copying test in outpatients with dementia. Brain Inj . 2004. ;18:889-898. [DOI] [PubMed] [Google Scholar]
  13. Maeshima S. , Itakura T., Nakagawa M., Nakai K., Komai N. Visuospatial impairment and activities of daily living in patient's with Parkinson's disease: a quantitative assessment of the cube-copying task. Am J Phys Med Rehabil . 1997;76:383-388. [DOI] [PubMed] [Google Scholar]
  14. Ericsson K. , Forssell L., Holmén K., Viitanen M., Winblad B. Copying and handwriting ability in the screening of cognitive dysfunction in old age. Arch Gerontol Geriatr . 1996;22:103-121. [DOI] [PubMed] [Google Scholar]
  15. Shimada Y., Meguro K., Kasai M., et al. Necker cube copying ability in normal elderly and Alzheimer's disease. A community-based study: the Tajiri project. Psychogeriatrics . 2006;6:4-9. [Google Scholar]
  16. Wallin A., Andreasen N., Eriksson S., et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord. 2007;23:150-160. [DOI] [PubMed] [Google Scholar]
  17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984. ;34:939-944. [DOI] [PubMed] [Google Scholar]
  18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. rev. Washington DC: American Psychiatric Association; 1987. [Google Scholar]
  19. Rosen W., Mohs R., Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry . 1984;141:1356-1364. [DOI] [PubMed] [Google Scholar]
  20. Paganini-Hill A., Clark LJ Preliminary assessment of cognitive function in older adults by clock drawing, box copying and narrative writing . Dement Geriatr Cogn Disord. 2007;23:74-81. [DOI] [PubMed] [Google Scholar]
  21. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord . 2007;24:118-124. [DOI] [PubMed] [Google Scholar]
  22. Folstein MF , Folstein SE, McHugh PF Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res. 1975;12: 182-198. [DOI] [PubMed] [Google Scholar]
  23. Green C., Mohs R., Schmeidler J., Aryan M., Davis K. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc. 1993;41:654-661. [DOI] [PubMed] [Google Scholar]
  24. Schneider LS , Olin JT Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr. 1996;8:277-290. [DOI] [PubMed] [Google Scholar]
  25. Han L., Cole M., Bellavance F., McCusker J., Primeau F. Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: a meta-analysis. Int Psychogeriatr. 2000;12:231-247. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES